Triple Immunotherapy Combo to Be Tested in Trial with Bladder Cancer Patients – Immuno-Oncology News
|
Triple Immunotherapy Combo to Be Tested in Trial with Bladder Cancer Patients
Immuno-Oncology News Two immunotherapies, INO–5401 and INO–9012, will be combined with immune checkpoint inhibitor Tecentriq (atezolizumab) in a Phase 1/2 trial to test the combo's safety and effectiveness in treating advanced bladder cancer. The trial, a result of … |
